Parabilis Sets Oct. 24 ESMO Presentation for Zolucatetide Data

Your call?🐂 Bullish🐻 Bearish

The update covers data through June 22 from an ongoing Phase 1/2 study. Dose-optimization results are intended to help select a dose and schedule for a planned Phase 3 desmoid tumor trial.